Global Travel Industry Embracing Autonomous UVD Robots
23.9.2020 16:02:00 EEST | Business Wire | Press release
With the latest forecast by the U.S. Travel Association by Tourism Economics predicting $505 billion in losses globally through the end of 2020, UVD Robots announced its autonomous disinfecting robot is being increasingly deployed within hotels, railways, and airports globally. UVD Robots’ mobile, fully autonomous robot integrates UVC light and a large number of disinfection-specialized apps to disinfect against viruses and bacteria not only on surfaces, but the air as well, providing a fully comprehensive infection control and prevention solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005177/en/
“Right now it’s critical for the hospitality industry to not only enhance how we protect travelers but also provide them with reassurance that we’re taking every possible step from check-in to check-out,” said Trish Berry, General Manager, YOTEL Boston. An extension of YOTEL’s operation #SmartStay safety measures, the UVD Robot, named ‘Vi-YO-Let’, will offer an even deeper level of disinfection throughout high-touch public spaces and select cabins at YOTEL Boston. Photo credit: YOTEL Boston.
“As the travel and hospitality industry looks to bring travelers back, they are working to meet new and heightened expectations for safety and cleanliness in order to build trust,” said Per Juul Nielsen, CEO of UVD Robots. “Because our UVD Robots are simple, safe and effective, we are working with an increasing number of hotels, airports, railways and others to bring hospital-grade disinfection solutions to these facilities. We couldn’t be more thrilled than to play a role in the recovery of this industry.”
Examples include:
- YOTEL Boston announced it has implemented the UVD Robots technology to clean select cabins when vacant with all high-touch public spaces also being disinfected upon closing.
- The Clarion Hotel & Congress Copenhagen Airport is applying UVD Robots to disinfect conference rooms and public areas.
- The Gerald R. Ford International Airport (GRR) is using UVD Robots to disinfect bathrooms, baggage claim areas, passenger checkpoints, TSA areas, and more after hours.
- UVD Robots has been operational at Heathrow Airport in London for several months.
- St. Pancras International railway station in London is deploying UVD Robots to disinfect washrooms at the stations.
Several additional projects are also currently being carried out in the travel industry within the Middle East, including the Hamad International Airport in Qatar.
About UVD Robots & Blue Ocean Robotics
UVD Robots is a subsidiary of one of the world's leading groups in the development of professional service robots, Blue Ocean Robotics, that also includes subsidiaries like GoBe Robots, PTR Robots and Mink Robots. Blue Ocean Robotics is headquartered in Europe’s “robot capital” Odense in Denmark.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005177/en/
Contact information
Merima Cikotic
Blue Ocean Robotics
mc@blue-ocean-robotics.com
+45 71-99-56-06
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom